ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
WALTHAM - ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that on March 31, 2023, the Compensation Committee of the... | April 4, 2023